These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31892925)

  • 1. [Loss to follow-up in patients treated for multidrug-resistant tuberculosis in EcuadorA Perda de seguimento de pacientes tratados para tuberculose multirresistente a medicamentos no Equador].
    Tatés-Ortega N; Álvarez J; López L; Mendoza-Ticona A; Alarcón-Arrascue E
    Rev Panam Salud Publica; 2019; 43():e91. PubMed ID: 31892925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.
    Charles F; Lin YD; Greig J; Gurra S; Morikawa R; Graham SM; Maha A
    Public Health Action; 2024 Sep; 14(3):85-90. PubMed ID: 39239161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis.
    Choi H; Mok J; Ae Kang Y; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
    ERJ Open Res; 2023 Jul; 9(4):. PubMed ID: 37583964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
    McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
    BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of loss to follow-up among adult tuberculosis patients in Southern Ethiopia: a retrospective follow-up study.
    Watumo D; Mengesha MM; Gobena T; Gebremichael MA; Jerene D
    BMC Public Health; 2022 May; 22(1):976. PubMed ID: 35568853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
    Kassa GM; Teferra AS; Wolde HF; Muluneh AG; Merid MW
    BMC Infect Dis; 2019 Sep; 19(1):817. PubMed ID: 31533661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?
    Htet KKK; Soe KT; Kumar AMV; Saw S; Win Maung HM; Myint Z; Khine TMM; Aung ST
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):385-392. PubMed ID: 29562985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hearing thresholds in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations.
    Sogebi OA; Fadeyi MO; Adefuye BO; Soyinka FO
    J Bras Pneumol; 2017; 43(3):195-201. PubMed ID: 28746530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What happened to patients with RMP-resistant/MDR-TB in Zambia reported as lost to follow-up from 2011 to 2014?
    Kasapo CC; Chimzizi R; Simwanza SC; Mzyece J; Chizema E; Mariandyshev A; Lee HY; Harries AD; Kapata N
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):887-893. PubMed ID: 28786797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects.
    Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Juliasih NN; Hadi C; Alfian IN
    BMC Pulm Med; 2021 Nov; 21(1):360. PubMed ID: 34758794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss to follow-up among patients diagnosed with spinal tuberculosis at a tertiary hospital in Western Cape Province, South Africa: A retrospective cohort study.
    Mann TN; Davis JH; Dyers R
    S Afr Med J; 2020 Mar; 110(4):284-290. PubMed ID: 32657739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
    PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Adamashvili N; Baliashvili D; Kuchukhidze G; Salindri AD; Kempker RR; Blumberg HM; Lomtadze N; Avaliani Z; Magee MJ
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):326-333. PubMed ID: 35351237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.